Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

• Status: Unknown status
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Determination of response rate Assessment of toxicity and determination of "time to progression"

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charite University, Berlin, Germany
• Collaborator: ribosepharm GmbH
• Treatments: Bendamustine Hydrochloride

Criteria

Inclusion Criteria:

• Patients with histological proven, curative non treatable small lung cell carcinoma

• Recurrence >8 weeks, > 1 year after 1st line treatment with platin- and etoposide polychemotherapy, without brain metastases

Exclusion Criteria:

• Brain metastases

• WHO-PS 3 - 4